Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?
The first vaccine against coronavirus disease could one day be made of mRNA. How is…
30/03/2020 - 7 minutes
mRNA: A New Technology Moving into the Mainstream
Messenger RNA (mRNA) technology is based on the idea that human cells can be used as on-demand factories to develop therapeutic proteins by giving them instructions in the form of mRNA. Although mRNA therapeutics and vaccines could be found in drug development pipelines before Covid-19 emerged, the pandemic suddenly moved the mRNA technology into the limelight.
Now, the world has seen mass vaccinations using mRNA-based vaccines developed by Moderna and Pfizer/BioNTech. But the mRNA technology holds promise for other indications as well, including cancer and rare diseases. Read on to learn how this new technology is moving into the mainstream with an influx of investments and new discoveries.
Show More
Editor's Picks for mRNA technology
- Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?
- Covid-19 Pandemic Drives RNA Therapeutics into the Mainstream
- EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19
- Next-Generation mRNA Vaccine Technology Unveiled in Series A Round
- Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
European Biotech Industry Report 2021
This report discusses how the Covid-19 pandemic impacted Europe’s life science industry and covers recent market trends, investments, and collaborations.
Go to ReportLatest mRNA technology Articles
CureVac Receives €80M from EU to Fund Coronavirus Vaccine Amid US Dispute
The German biotech CureVac -- which is developing an mRNA vaccine against coronavirus -- has…
17/03/2020 - 2 minutes
EU Project Receives €15M to Bring mRNA Therapy to a Wider Audience
An EU research project has launched with the aim of bringing mRNA treatments to a…
08/11/2019 - 4 minutes
This Biotech Uses Messenger RNA to Treat Lethal Lung Inflammation
Based close to Berlin, Germany, the biotech startup Pantherna Therapeutics is developing a messenger RNA…
02/08/2019 - 4 minutes
BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer
In one of the biggest ever funding rounds in European biotech, the German company BioNTech…
09/07/2019 - 3 minutes
Rapid Response mRNA Vaccine Facility Gets €30M Funding
An mRNA vaccine facility, run by the German biotech CureVac, has received a €30M development…
01/03/2019 - 3 minutes
What Does the Largest Biotech IPO Ever Mean for European Biotech?
With a massive €530M ($604M) raised, US-based Moderna has made a record biotech IPO. The…
11/12/2018 - 3 minutes
Pfizer Offers €374M for German mRNA Flu Vaccine
BioNTech, based in Mainz, Germany, has entered into a partnership with Pfizer worth up to…
16/08/2018 - 2 minutes
German Biotech Raises Record $270M Series A for Individualized Cancer Therapies
BioNTech will dedicate its huge fundraising to develop personalized cancer immunotherapies using CAR-T, TCR and…
04/01/2018 - 2 minutes
US Biotech Unicorn Steps up Competition for BioNTech’s mRNA Personalized Cancer Vaccine
Moderna Therapeutics has started dosing patients with an mRNA-based personalized cancer vaccine that resembles another…
15/11/2017 - 2 minutes
Battle of the Biotech Unicorns: CureVac vs. Moderna
An interview never seen before. We brought together the founders and CEOs of the two…
06/11/2017 - 4 minutes
AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure
AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis' failed…
02/11/2017 - 2 minutes
